Journal
FUTURE MICROBIOLOGY
Volume 3, Issue 2, Pages 135-144Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/17460913.3.2.135
Keywords
derivatives; K+ inhibition; macrophages; MDR-TB; Mycobarterium tuberculosis; phenothiazines; thioridazine; XDR-TB
Categories
Funding
- Fundacao para a Ciencia e a Tecnologia (FCT) of Portugal [EU-FSE/FED-ERPOCTI-37579/FCB/2001, EU-FSE/FEDER-POCI/SAUMMO/59370/2004]
- FCT (Portugal) [SFRH/BD/1431912003]
Ask authors/readers for more resources
Therapy of multidrug-resistant (MDR)-TB is highly problematic; that of extensively drug-resistant (XDR)-TB even more so. Both infections result in high mortality, especially if the patient is coinfected with HIV or presents with AIDS. Selection of therapy for these infections is limited and, for most situations, it is performed 'blind'. However, there is a solution for the selection of effective therapy and this is presented herein. Ideal therapy of the patient infected with MDR-TB or XDR-TB can be determined a priori by the mycobacteriology laboratory. This would involve the isolation of the patient's macrophages, the phagocytosis of the mycobacterial isolate and the presentation of the antitubercular agent to the macrophage-bacterium complex. This system is reviewed in its entirety and its potential and feasibility are supported by hard experimental demonstrations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available